Cadila Pharmaceuticals has launched Ciledge Trio, a fixed‑dose combination therapy designed to deliver sustained blood pressure (BP) control with improved tolerability and enhanced patient adherence in hypertensive patients, especially those with underlying heart conditions. The new product reinforces the company’s focus on advanced cardiovascular care and unmet needs in hypertension management.
Ciledge Trio combines three well‑established antihypertensive agents: Cilnidipine (CCB), Telmisartan (ARB), and Metoprolol (a β1‑selective blocker), each acting through complementary mechanisms to provide stronger and more consistent BP reduction. Clinical evidence supports combination therapy as a superior strategy for sustained control and enhanced cardioprotection, particularly in patients with co‑existing cardiac conditions or a history of myocardial infarction.
Cilnidipine is associated with up to ten‑fold lower incidence of pedal edema compared with conventional CCBs, while its combination with telmisartan offers effective, sustained BP control and a favorable safety profile, including benefits for patients with diabetes and chronic kidney disease. Adding metoprolol further improves heart‑rate control and overall cardiovascular protection.
By integrating all three agents into a single‑pill formulation, Ciledge Trio significantly reduces pill burden, which is known to improve treatment adherence and long‑term clinical outcomes. The therapy is positioned especially for hypertensive patients with underlying cardiac issues such as angina, myocardial infarction, and heart failure, where consistent BP control and cardioprotection are critical.
The launch is supported by Cadila’s proprietary Tri‑tab technology, an innovative triple‑layered tablet platform that goes beyond conventional bi‑layered designs. This system enables the rational combination of three active ingredients in a single, high‑purity delivery form, ensuring enhanced stability, reduced drug–drug incompatibility, and consistent plasma drug levels. The precise three‑layer structure also improves absorption of all three components, offering a therapeutic advantage over standard film‑coated tablets.
On the launch, Dr. Rajiv I. Modi, CMD, Cadila Pharmaceuticals, said: “Cadila Pharmaceuticals reinforces its commitment to addressing unmet needs in hypertension management. This guideline‑driven combination is designed to deliver efficacy, safety, and long‑term cardiovascular protection, key elements for improving patient outcomes in real‑world clinical practice.”
With Ciledge Trio, Cadila strengthens its cardiovascular portfolio and contributes to better hypertension control, supporting broader efforts to reduce India’s long‑term cardiovascular disease burden.
